SlideShare une entreprise Scribd logo
1  sur  7
Télécharger pour lire hors ligne
Determination of minimum inhibitory concentrations (MICs) of
antibacterial agents by agar dilution
European CommitteeforAntimicrobial SusceptibilityTesting (EUCAST) of the European Societyof ClinicalMicrobiologyand Infectious
Diseases(ESCMID)
INTRODUCTION
Dilution methods are used to determine the minimum inhibi-
toryconcentrations (MICs) of antimicrobial agents and are the
reference methods for antimicrobial susceptibility testing
against which other methods, such as disk di¡usion, are cali-
brated. MIC methods are widely used in the comparative test-
ing of new agents. In clinical laboratories they are used to
establish the susceptibility of organisms that give equivocal
results in disk tests, for tests on organisms where disk tests may
be unreliable, and when a more accurate result is required for
clinical management.
In dilution tests, microorganisms are tested for their ability
to produce visible growth on a series of agar plates (agar dilu-
tion) or in microplate wells of broth (broth microdilution)
containing dilutions of the antimicrobial agent. The lowest
concentration of an antimicrobial agent that will inhibit the
visible growth of a microorganism is known as the MIC.
The agar dilution method described in this document is
based on that described in the report of an international colla-
borative study of antimicrobial susceptibility testing [1] and is
very similar to those described and recommended in many
countries, including France [2], Germany [3], Norway [4],
Sweden [5], the UK [6] and the USA [7].
MEDIUM
Although several susceptibility testing media are available in
Europe, a clear choice for a reference medium remains to be
determined. Mueller^Hinton (MH) agar shows no perfor-
mance advantages over some other media but is probably the
most widely used medium internationally, and there is a USA
National Committee for Clinical Laboratory Standards
(NCCLS) document which describes procedures for evaluat-
ing MH agar [8]. MH agar which meets the requirements of
the NCCLS standard [8] is considered the reference medium.
Supplements should not be used unless necessary for
growth of the organisms. Five per cent de¢brinated blood is
added for fastidious organisms such as streptococci and Morax-
ella catarrhalis. Several supplements for Haemophilus spp. and
Neisseria spp. have been suggested but evidence of perfor-
mance is needed. Five per cent de¢brinated blood with 20 mg/
L NAD, 5% chocolated blood, and supplemented GC agar
have been suggested.
ANTIMICROBIAL AGENTS
Obtain antimicrobial powders directly from the manufacturer
or from commercial sources.The agent must be supplied with
a stated potency (mg or International Units per g powder, or as
a percentage potency), an expiry date and details of recom-
mended storage conditions. Store powders in sealed contain-
ers in the dark at 4 
C with a desiccant unless otherwise
recommended by the manufacturer. Ideally, hygroscopic
agents should be dispensed into aliquots, and one aliquot used
on each test occasion. Allow containers to warm to room tem-
perature before opening them to avoid condensation of water
on the powder.
Preparation of stock solutions
Use an analytical balance when weighing agents. Allowance
for the potency of the powder can be made by use of the fol-
lowing formula:
Weight of powder …mg† ˆ
Volume of solvent …mL† Â Concentration …mgaL†
Potency of powder …mgag†
Alternatively, given a weighed amount of antimicrobial pow-
der, the volume of diluent needed may be calculated from the
formula:
Weight of solvent …mL† ˆ
Weight of powder …mg† Â Potency of powder …mgag†
Concentration …mgaL†
Concentrations of stock solutions should be 1000 mg/L or
greater, although the solubility of some agents will be limit-
ing. The actual concentrations of stock solutions will depend
on the method of preparing working solutions. Manufac-
turers' recommendations for solvents and diluents should be
followed, but where possible agents should be dissolved and
diluted in sterile distilled water. Some agents that require
alternative solvents are listed in Table1. Sterilization of solu-
tions is not usually necessary. If required, sterilization should
EUCAST DEFINITIVE DOCUMENT E.Def 3.1 JUNE 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
be by membrane ¢ltration, and samples before and after steri-
lization must be compared by assay to ensure that adsorption
to the membrane has not occurred. Unless otherwise
instructed by the manufacturer, store stock solutions frozen in
aliquots at À20 
C or below. Most agents will keep at À60 
C
for at least 6 months. Stock solutions must be frozen as soon as
possible after preparation, used promptly on defrosting and
not re-frozen.
Preparation of working solutions
The range of concentrations tested will depend on the organ-
isms and antimicrobial agent being tested, but a two-fold
dilution series based on 1mg/L is conventionally used.
Twenty-milliliter volumes of agar are commonly used in 9-
cm Petri dishes for agar dilution MICs. Two alternative dilu-
tion schemes are given inTables 3 and 4. Both schemes involve
adding 19-mL volumes of molten agar to 1-mL volumes of
antimicrobial solution. The more conventional method is
based on diluting a 10 240 mg/L stock solution, always mea-
suring 1-mL volumes of antimicrobial solution (Table 2). The
other method (Table 3) is based on diluting a 10 000 mg/L
stock solution and involves measuring various volumes of
antimicrobial solution by the use of high-precision variable-
volume micropipettes, which are now widely available. An
alternative to the method in Table 3 is to omit the distilled
water added to make antimicrobial volumes up to 1mL and
instead to add a variable volume of molten agar to make the
total volume 20 mL.
PREPARATION OF PLATES
Prepare agar as recommended by the manufacturer. Allow
the sterilized agar to cool to 50 
C in a water-bath. Prepare a
dilution series of antimicrobial agents, as above, in 25^30-mL
containers. Include a drug-free control. Add 19 mL of molten
agar to each container, mix thoroughly, and pour the agar into
prelabeled sterile Petri dishes on a level surface. Allow the
plates to set at room temperature and dry the plates so that no
drops of moisture remain on the surface of the agar. Do not
overdry plates.
Plates should not be stored unless the agents have been
shown to be stable on storage. Clavulanic acid and carbape-
nems are particularly unstable.
Table1 Solvents and diluents for antimicrobial agents requiring solvents other than water
Antimicrobial agent Solvent Diluent
Amoxycillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Ampicillin Phosphate buffer 0.1 M, pH 8.0 Phosphate buffer 0.1 M, pH 6.0
Azithromycin Ethanol 95% Water
Aztreonam Saturated sodium bicarbonate solution Water
Ceftazidime Saturated sodium bicarbonate solution Water
Chloramphenicol Ethanol 95% Water
Clavulanic acid Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Erythromycin Ethanol 95% Water
Fluoroquinolones Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Fusidic acid Ethanol 95% Water
Imipenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2
Mezlocillin Methanol Water
Meropenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2
Nalidixic acid Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Nitrofurantoin Dimethylformamide Phosphate buffer 0.1 M, pH 8.0
Rifampicin Methanol Water
Sulbactam Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Sulfonamides Half volume water,
a minimum volume of 0.1 M NaOH to dissolve,
then make up to total volume with water
Water
Ticarcillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0
Trimethoprim Half volume water,
a minimum volume of 0.1 M lactic acid or 0.1 M HCl to dissolve,
then make up to total volume with water
Water
äò Clinical Microbiology and Infection, Volume 6 Number 9, September 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
Table 2 Preparation of dilutions of agents for use in agar dilution susceptibility tests
Antimicrobial
concentration (mg/L)
in stock solution
Volume stock
solution (mL)
Volume
distilled water (mL)
Antimicrobial
concentration
obtained (mg/L)
Final concentration in
medium after addition
of 19 mL of agar
10 240 1 0 10 240 512
10 240 1 1 5120 256
10 240 1 3 2560 128
2560 1 1 1280 64
2560 1 3 640 32
2560 1 7 320 16
320 1 1 160 8
320 1 3 80 4
320 1 7 40 2
40 1 1 20 1
40 1 3 10 0.5
40 1 7 5 0.25
5 1 1 2.5 0.125
5 1 3 1.25 0.06
5 1 7 0.625 0.03
0.625 1 1 0.3125 0.015
0.625 1 3 0.1562 0.008
0.625 1 7 0.0781 0.004
Table 3 Alternative method of preparation of dilutions of antimicrobial agents for use in agar dilution susceptibility tests
Antimicrobial
concentration
(mg/L) in stock
Volume stock
solution (mL)
Volume distilled
water (mL)
Antimicrobial
concentration
obtained (mg/L)
Final concentration in
medium after addition
of 19 mL of agar
10 000 1 9 1000 ±
10 000 0.1 9.9 100 ±
100 1 9 10 ±
100 0.1 9.9 1 ±
10 000 1.024 0 10 240 512
10 000 0.512 0.488 5120 256
10 000 0.256 0.744 2560 128
10 000 0.128 0.872 1280 64
1000 0.64 0.36 640 32
1000 0.32 0.68 320 16
1000 0.16 0.84 160 8
100 0.8 0.2 80 4
100 0.4 0.6 40 2
100 0.2 0.8 20 1
10 1 0 10 0.5
10 0.5 0.5 5 0.25
10 0.25 0.75 2.5 0.125
10 0.125 0.875 1.25 0.06
1 0.625 0.375 0.625 0.03
1 0.313 0.687 0.3125 0.015
1 0.156 0.844 0.1562 0.008
1 0.078 0.922 0.0781 0.004
äEUCAST De®nitive Document
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
PREPARATION OF INOCULUM
Standardize the density of inoculum to give 104
colony-form-
ing units (CFU) per spot on the agar. Use four or ¢ve colonies
of a pure culture to avoid selecting an atypical variant. The
inoculum may be prepared by emulsifying overnight colonies
from an agar medium or by diluting a broth culture.The broth
used must not be antagonistic to the agent tested. A 0.5 McFar-
land standard may be used for visual comparison to adjust the
suspension to a density equivalent to approximately 108
CFU/
mL. Alternatively, inocula can be adjusted photometrically.
Dilute the suspensions of organisms in 0.85% saline or broth
to give 107
CFU/mL. Plates must be inoculated within 30 min
of standardizing the inoculum, to avoid changes in inoculum
density.
INOCULATION OF PLATES
Mark the plates so that the orientation is obvious. Transfer
diluted bacterial suspensions to the wells of an inoculum-
replicating apparatus. Use the apparatus to transfer the inocula
to the series of agar plates, including a control plate without
antimicrobial agent. Replicator pins 2.5 mm in diameter will
transfer about1 mL, i.e. an inoculum of104
CFU/spot. Alterna-
tively, a micropipette or standard loop may be used to inocu-
late plates. Allow the inoculum spots to dry at room
temperature before inverting the plates for incubation.
INCUBATION OF PLATES
Incubate plates at 35^37 
C in air for 18 h. In order to avoid
uneven heating, do not stack plates more than ¢ve high. If the
incubation period is extended for slow-growing organisms,
the stability of the agent over the incubation period must be
assessed by the inclusion of control strains with known MICs.
Avoid incubation in an atmosphere containing 5% CO2 unless
necessary for growth of the organisms (e.g. Neisseria spp.).
Incubate methicillin/oxacillin susceptibility tests on staphylo-
cocci at 30 
C.
READING RESULTS
The MIC is the lowest concentration of the agent that comple-
tely inhibits visible growth as judged by the naked eye, disre-
garding a single colony or a thin haze within the area of the
inoculated spot. A trailing endpoint with a small number of
colonies growing on concentrations several dilutions above
that which inhibits most organisms should be investigated by
subculture and retesting. Such trailing endpoints may indicate
contamination, resistant variants, b-lactamase-producing
organisms, or, if incubation is prolonged, regrowth of suscep-
tible organisms following deterioration of the agent. With
sulfonamides and trimethoprim, endpoints may be seen as a
reduction in growth, and a haze of growth may be seen at sev-
eral dilutions above the actual MIC.
FASTIDIOUS ORGANISMS
Testing of fastidious organisms may require supplementation
of the medium, enrichment of the incubation atmosphere
with 5% CO2, or extension of the incubation time.The e¡ect
of any alterations in test conditions must be assessed by the
inclusion of appropriate control organisms.
METHICILLIN/OXACILLIN SUSCEPTIBILITY TESTS
ON STAPHYLOCOCCI
A combination of test conditions a¡ects the expression of
intrinsic resistance to b-lactam agents in staphylococci. The
following apply to tests with staphylococci and all b-lactam
agents:
1. Add 2% NaCl to the medium.
2. Incubate tests at 30 
C (note that some coagulase-negative
strains do not grow well at 30 
C and may require incubation
for 48 h).
3. Incubate tests for 24 h. Continue incubation for a further
24 h for coagulase-negative staphylococci.
Penicillinase hyperproducing strains of Staphylococcus aureus
may have methicillin/oxacillin MICs raised by one or two
two-fold dilution steps compared with other penicillinase-
producing strains.
TESTS ON bb-LACTAMASE-PRODUCING
ORGANISMS
When testing organisms that produce extracellular b-lacta-
mases, the MICs of penicillins and cephalosporins may be
markedly a¡ected by the density of inoculum. The standard
inoculum may result in MICs only slightly higher than those
obtained with susceptible strains. b-Lactamase production can
be more reliably detected in staphylococci, gonococci, Haemo-
philus in£uenzae and Moraxella catarrhalis by de¢nitive tests such
as nitroce¢n-based techniques. Among Gram-negative
organisms, the e¡ect of the inoculum depends on the amount
of enzyme produced, and the activity of the enzyme against
the particular penicillin or cephalosporin under test. E¡ective
standardization of the inoculum is necessary to avoid large
variations in MIC results.
QUALITY CONTROL
Routine quality control is achieved by the use of control
strains, e.g. as shown in Table 4. Working cultures of control
strains may be stored on digest agar slopes and subcultured
äá Clinical Microbiology and Infection, Volume 6 Number 9, September 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
Table4TargetMICsforcontrolorganismsonMueller±Hinton(MH)andIso-Sensitest(IS)mediawithoutblood
Antimicrobialagent
Escherichia
coli
ATCC25922
NCTC12241
CIP76.24
MH(IS)agar
Escherichia
coli
ATCC10536
NCTC10418
CIP54.127
ISagar
Pseudomonas
aeruginosa
ATCC27853
NCTC12934
CIP76.110
(MH)ISagar
Pseudomonas
aeruginosa
ATCC25668
NCTC10662
CIP103837
ISagar
Staphylococcus
aureus
ATCC29213
NCTC12973
CIP103429
MH(IS)agar
Staphylococcus
aureus
ATCC9144
NCTC6571
CIP53.154
ISagar
Enterococcus
faecalis
ATCC29212
NCTC12697
CIP103214
MH(IS)agar
Amikacin1(1)0.52(2)22(2)1128(128)
Ampicillin4(4)2±±0.50.061(1)
Amoxycillin4(4)2±±±0.125±(0.5)
Amoxycillin/clavulanicacid4/2(4/2)2/1±±±(0.25/0.125)0.125/0.060.5/0.25(0.5/0.25)
Azithromycin±±±±1(0.125)0.125
Aztreonam0.125(0.25)0.034(2)4±±±
Carbenicillin82323240.532
Cefaclor2(2)1±±2(1)1±
Cefamandole0.5±±0.50.25±
Cefazolin2±±±0.5±±
Cefepime0.03±2(2)±2±±
Ce®xime0.5(0.25)0.06±1616(16)8±
Cefonicid0.5±±±2±±
Cefoperazone0.25±4±2±±
Cefotaxime0.125(0.06)0.038(8)82(1)0.5±(32)
Cefotetan0.1250.06±±84±
Cefoxitin24±±22±
Cefpirome±(0.03)0.03±(1)4±(0.5)±±(16)
Cefpodoxime0.5(0.25)0.25±1282(2)0.25±
Cefsulodin±±±2±±±
Ceftazidime0.125(0.25)0.062(1)18(8)1±
Ceftizoxime0.060.00832±42±
Ceftriaxone0.060.0316(8)82(2)±±
Cefuroxime42±±1(1)0.5±
Cephalexin8(8)4±±4(4)1±
Cephalothin8(8)4±±0.25(0.25)0.5±(16)
Cephradine±4±±±2±
Chloramphenicol42±1284(2)28(4)
Cipro¯oxacin0.0080.0150.5(0.25)0.250.25(0.5)0.1250.5(1)
Clarithromycin±±±±0.250.12±
Clindamycin±±±±0.125(0.06)0.068(8)
Colistin10.50.52±±±
Enoxacin0.1250.254110.54
Erythromycin±±±±0.5(0.25)0.1252(4)
Fleroxacin0.060.06210.50.54
Fusidicacid±±±±±(0.06)0.06±(2)
Gati¯oxacin±0.015±1±0.03±
äâEUCAST De®nitive Document
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
Antimicrobialagent
Escherichia
coli
ATCC25922
NCTC12241
CIP76.24
MH(IS)agar
Escherichia
coli
ATCC10536
NCTC10418
CIP54.127
ISagar
Pseudomonas
aeruginosa
ATCC27853
NCTC12934
CIP76.110
(MH)ISagar
Pseudomonas
aeruginosa
ATCC25668
NCTC10662
CIP103837
ISagar
Staphylococcus
aureus
ATCC29213
NCTC12973
CIP103429
MH(IS)agar
Staphylococcus
aureus
ATCC9144
NCTC6571
CIP53.154
ISagar
Enterococcus
faecalis
ATCC29212
NCTC12697
CIP103214
MH(IS)agar
Gentamicin0.5(0.5)0.251(1)20.25(0.25)0.1258(8)
Imipenem0.125(0.125)0.062(1)20.03(0.015)0.0151(0.5)
Kanamycin2(1)1±12232
Levo¯oxacin0.0160.031(0.5)0.50.125(0.25)0.1250.5
Linezolid±±±±±0.5±
Loracarbef1(1)0.5±±1(1)0.5±
Mecillinam±(0.125)0.125±8±(64)8±
Methicillin±±±±1(2)1±
Meropenem0.016(0.008)0.0150.5(0.25)20.06(0.06)0.034(2)
Mezlocillin4216820.52
Moxalactam0.250.0316888±
Moxi¯oxacin±0.03±(2)2±0.06±(0.25)
Mupirocin±±±±±(0.125)0.25±
Nalidixicacid22±±±(128)±±
Neomycin±±±32±0.125±
Netilmicin0.50.521±0.258
Nitrofurantoin84±±16(16)88(8)
Nor¯oxacin0.060.062(1)11(1)0.252(2)
O¯oxacin0.030.062(1)10.250.252(2)
Oxacillin±±±±0.25(0.5)0.25±
Pe¯oxacin±0.06±0.5±0.25±
Penicillin±±±±0.5(0.125)0.032(2)
Piperacillin2(2)0.52(2)42(1)0.252(2)
Piperacillin/tazobactam2/4±2/4±0.5/4±2/4
Quinupristin/dalfopristin±±±±0.5(0.25)0.1254(1)
Rifampicin161632±0.016(0.004)0.0042(2)
Sul®soxazole16±±±64±64
Sulfamethoxazole±16±±±64±
Teicoplanin±±±±0.5(0.5)0.250.125(0.25)
Temocillin±2±±±±±
Tetracycline2116(32)±0.5(0.5)0.12516(16)
Ticarcillin41161640.532
Ticarcillin/clavulanicacid4/2±16/2(16/4)32/41/2±32/2
Tobramycin0.5(0.5)0.250.5(0.5)0.50.25(0.5)0.12516
Trimethoprim10.125±322(0.5)0.25±(0.25)
Trimethoprim/sulfamethoxazole±±±±±±±
Vancomycin±±±±1(1)0.52(2)
ATCCistheAmericanTypeCultureCollection,12301ParklawnDrive,Rockville,MD20852,USA.NCTCistheNationalCollectionofTypeCultures,CentralPublicHealthLaboratory,61
ColindaleAvenue,LondonNW95HT,UK.CIPisCollectiondel'InstitutPasteur,25±28RueduDocteurRoux,75724ParisCedex15,France.
Table4continued
äã Clinical Microbiology and Infection, Volume 6 Number 9, September 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
weekly. Working cultures should be replaced monthly from
lyophilized or frozen cultures (at À60 
C or below).
Test colonies of control cultures as recommended for test
cultures. Include control cultures with each batch of tests, and
test new lots of agar before they are used routinely. In general,
MICs of control organisms should be within one two-fold
dilution step of the target values given in Table 4. As well as
target values for tests on the reference medium, MH agar, tar-
get values for control strains tested on Iso-Sensitest agar are
included for comparison. In addition:
1. The control plate without antimicrobial agents must show
adequate growth of both test and control strains.
2. Plate a sample of inoculum prepared for each strain on a
suitable agar medium to ensure that the inoculum is apure cul-
ture.
3. Occasionally check that the method of producing the cor-
rect inoculum density is working by counting the number of
organisms in the inocula.
4. Check that endpoints are read consistently by all sta¡ inde-
pendently reading a selection of tests.
REVISIONS
Proposals for revisions of this document should be sent to
EUCAST via EUCAST Secretariat, Cornelia Hasselmann,
Martin-Buber-Weg 17, D-81245 Munich, Germany (Fax: ‡
49 89 89712004; E-mail: Cornelia.Hasselmann@t-online.de)
REFERENCES
1. Ericsson H, Sherris JC. Antibiotic sensitivity testing. Report of an
international collaborative study. Acta Pathol Microbiol Scand Sect B
1971; 217(suppl): 1^90.
2. Comite¨ l'Antibiogramme de la Socie¨ te¨ Franc,aise de Microbiologie.
Technical recommendations for in vitro susceptibility testing. Clin
Microbiol Infect1996; 2(suppl1): S11^25.
3. Deutsches Institut fu« r Normung. Methods for the determination of sus-
ceptibility of pathogens (except mycobacteria) to antimicrobial agents. MIC
breakpoints of antibacterial agents. Berlin: DIN, 1998; suppl 1: 58940^
4.
4. Norwegian Working Group on Antibiotics. Susceptibility testing
of bacteria and fungi. ScandJInfectDis1997;103(suppl): 1^36.
5. Olsson-Liljequist B, Larsson P,Walder M, Mio« rner H. Antimicro-
bial susceptibility testing in Sweden III. Methodology for suscept-
ibility testing. ScandJInfectDis1997;105(suppl): 13^23.
6. BSAC Working Party. A guide to sensitivity testing. J Antimicrob
Chemother1991; 27(suppl D):1^50.
7. National Committee for Clinical Laboratory Standards. Methods
for dilution antimicrobial susceptibility tests for bacteria that growaerobically,
5th edn. Approved Standard M7-A5.Wayne, PA: NCCLS, 2000.
8. National Committee for Clinical Laboratory Standards. Protocols
for evaluating dehydrated Mueller^Hinton agar. Approved Standard M6-
A.Wayne, PA: NCCLS,1996.
ääEUCAST De®nitive Document
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515

Contenu connexe

Tendances

Sterility testing 112070804014
Sterility testing 112070804014Sterility testing 112070804014
Sterility testing 112070804014
Patel Parth
 
in process quality control test for ophthalmic and parenterals
in process quality control test for ophthalmic and parenterals in process quality control test for ophthalmic and parenterals
in process quality control test for ophthalmic and parenterals
Henisha Patel
 

Tendances (20)

BET testing USP85 an Introduction
BET testing USP85 an Introduction BET testing USP85 an Introduction
BET testing USP85 an Introduction
 
Parentral
ParentralParentral
Parentral
 
Sterility test
Sterility testSterility test
Sterility test
 
Sterility testing 112070804014
Sterility testing 112070804014Sterility testing 112070804014
Sterility testing 112070804014
 
PARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATIONPARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATION
 
ANALYSIS OF INJECTABLE DOSAGE FORM
ANALYSIS OF INJECTABLE  DOSAGE FORMANALYSIS OF INJECTABLE  DOSAGE FORM
ANALYSIS OF INJECTABLE DOSAGE FORM
 
processing and manufacturing of small volume parental
processing and manufacturing of small volume parentalprocessing and manufacturing of small volume parental
processing and manufacturing of small volume parental
 
Pyrogen test parth
Pyrogen test parthPyrogen test parth
Pyrogen test parth
 
2.6.12. microbiological examination of non sterile products (total viable aer...
2.6.12. microbiological examination of non sterile products (total viable aer...2.6.12. microbiological examination of non sterile products (total viable aer...
2.6.12. microbiological examination of non sterile products (total viable aer...
 
5.1.3. Efficacy of antimicrobial preservation (EP 5.0)
5.1.3. Efficacy of antimicrobial preservation (EP 5.0)5.1.3. Efficacy of antimicrobial preservation (EP 5.0)
5.1.3. Efficacy of antimicrobial preservation (EP 5.0)
 
6. Sterility testing
6. Sterility testing6. Sterility testing
6. Sterility testing
 
Pilot plant parenteal production
Pilot plant parenteal productionPilot plant parenteal production
Pilot plant parenteal production
 
Phytochemical and acute toxicity study of leaves of artocarpus heterophyllus lam
Phytochemical and acute toxicity study of leaves of artocarpus heterophyllus lamPhytochemical and acute toxicity study of leaves of artocarpus heterophyllus lam
Phytochemical and acute toxicity study of leaves of artocarpus heterophyllus lam
 
Antimicrobial Effectiveness test
Antimicrobial Effectiveness testAntimicrobial Effectiveness test
Antimicrobial Effectiveness test
 
Rapid sterility testing
Rapid sterility testingRapid sterility testing
Rapid sterility testing
 
in process quality control test for ophthalmic and parenterals
in process quality control test for ophthalmic and parenterals in process quality control test for ophthalmic and parenterals
in process quality control test for ophthalmic and parenterals
 
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORMPARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
 
manufacturing of parenterals
manufacturing of parenteralsmanufacturing of parenterals
manufacturing of parenterals
 
Sterility testing of Pharmaceutical Products
Sterility testing of Pharmaceutical ProductsSterility testing of Pharmaceutical Products
Sterility testing of Pharmaceutical Products
 
Muntingia calabura ( Singapore cherry) project PPT
Muntingia calabura ( Singapore cherry) project PPTMuntingia calabura ( Singapore cherry) project PPT
Muntingia calabura ( Singapore cherry) project PPT
 

Similaire à Determination of minimum inhibitory concentrations (mi cs) of 2000

Bioassay 112070804012
Bioassay 112070804012Bioassay 112070804012
Bioassay 112070804012
Patel Parth
 
antifungalsensitivity-18062714320 8.pptx
antifungalsensitivity-18062714320                                  8.pptxantifungalsensitivity-18062714320                                  8.pptx
antifungalsensitivity-18062714320 8.pptx
vasudevjayakottarath
 
IPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptxIPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptx
SohailSheikh62
 
manufacturing of Parenterals.pdf
manufacturing of Parenterals.pdfmanufacturing of Parenterals.pdf
manufacturing of Parenterals.pdf
SohailSheikh62
 

Similaire à Determination of minimum inhibitory concentrations (mi cs) of 2000 (20)

Usp 40 -71 sterility tests
Usp 40 -71 sterility testsUsp 40 -71 sterility tests
Usp 40 -71 sterility tests
 
Antifungal Susceptibility Test
Antifungal Susceptibility TestAntifungal Susceptibility Test
Antifungal Susceptibility Test
 
microbial assay antibiotics, vitamins, amino acids
microbial assay antibiotics,  vitamins,  amino acidsmicrobial assay antibiotics,  vitamins,  amino acids
microbial assay antibiotics, vitamins, amino acids
 
Bioassay 112070804012
Bioassay 112070804012Bioassay 112070804012
Bioassay 112070804012
 
Microbiological assays- Pharmacuetical Microbiology
Microbiological assays- Pharmacuetical MicrobiologyMicrobiological assays- Pharmacuetical Microbiology
Microbiological assays- Pharmacuetical Microbiology
 
Peptone water with na cl
Peptone water with na clPeptone water with na cl
Peptone water with na cl
 
antifungalsensitivity-18062714320 8.pptx
antifungalsensitivity-18062714320                                  8.pptxantifungalsensitivity-18062714320                                  8.pptx
antifungalsensitivity-18062714320 8.pptx
 
Sterility testing products (solids, liquids, ophthalmic and other sterile pro...
Sterility testing products (solids, liquids, ophthalmic and other sterile pro...Sterility testing products (solids, liquids, ophthalmic and other sterile pro...
Sterility testing products (solids, liquids, ophthalmic and other sterile pro...
 
part6-230110081003-34eff4a5 (1).pdf
part6-230110081003-34eff4a5 (1).pdfpart6-230110081003-34eff4a5 (1).pdf
part6-230110081003-34eff4a5 (1).pdf
 
Fumonisin
FumonisinFumonisin
Fumonisin
 
B12 ASSAY MEDIUM (VITAMIN B12 ASSAY MEDIUM) (USING L. LEICHMANNII)
B12 ASSAY MEDIUM (VITAMIN B12 ASSAY MEDIUM) (USING L. LEICHMANNII)B12 ASSAY MEDIUM (VITAMIN B12 ASSAY MEDIUM) (USING L. LEICHMANNII)
B12 ASSAY MEDIUM (VITAMIN B12 ASSAY MEDIUM) (USING L. LEICHMANNII)
 
Broth microdilution reference methodology
Broth microdilution reference methodologyBroth microdilution reference methodology
Broth microdilution reference methodology
 
Total aflatoxin
Total aflatoxinTotal aflatoxin
Total aflatoxin
 
Don
DonDon
Don
 
EVALUATION OF EFFICACY OF ANTIMICOBIAL PRESERVATIVE
EVALUATION OF EFFICACY OF ANTIMICOBIAL PRESERVATIVEEVALUATION OF EFFICACY OF ANTIMICOBIAL PRESERVATIVE
EVALUATION OF EFFICACY OF ANTIMICOBIAL PRESERVATIVE
 
IPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptxIPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptx
 
Zearalenone
ZearalenoneZearalenone
Zearalenone
 
manufacturing of Parenterals.pdf
manufacturing of Parenterals.pdfmanufacturing of Parenterals.pdf
manufacturing of Parenterals.pdf
 
Methods for standardization of antibiotics
Methods for standardization of antibiotics Methods for standardization of antibiotics
Methods for standardization of antibiotics
 
3. Antimicrobial Effectiveness Final.pptx
3. Antimicrobial Effectiveness Final.pptx3. Antimicrobial Effectiveness Final.pptx
3. Antimicrobial Effectiveness Final.pptx
 

Dernier

Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 

Dernier (20)

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 

Determination of minimum inhibitory concentrations (mi cs) of 2000

  • 1. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution European CommitteeforAntimicrobial SusceptibilityTesting (EUCAST) of the European Societyof ClinicalMicrobiologyand Infectious Diseases(ESCMID) INTRODUCTION Dilution methods are used to determine the minimum inhibi- toryconcentrations (MICs) of antimicrobial agents and are the reference methods for antimicrobial susceptibility testing against which other methods, such as disk di¡usion, are cali- brated. MIC methods are widely used in the comparative test- ing of new agents. In clinical laboratories they are used to establish the susceptibility of organisms that give equivocal results in disk tests, for tests on organisms where disk tests may be unreliable, and when a more accurate result is required for clinical management. In dilution tests, microorganisms are tested for their ability to produce visible growth on a series of agar plates (agar dilu- tion) or in microplate wells of broth (broth microdilution) containing dilutions of the antimicrobial agent. The lowest concentration of an antimicrobial agent that will inhibit the visible growth of a microorganism is known as the MIC. The agar dilution method described in this document is based on that described in the report of an international colla- borative study of antimicrobial susceptibility testing [1] and is very similar to those described and recommended in many countries, including France [2], Germany [3], Norway [4], Sweden [5], the UK [6] and the USA [7]. MEDIUM Although several susceptibility testing media are available in Europe, a clear choice for a reference medium remains to be determined. Mueller^Hinton (MH) agar shows no perfor- mance advantages over some other media but is probably the most widely used medium internationally, and there is a USA National Committee for Clinical Laboratory Standards (NCCLS) document which describes procedures for evaluat- ing MH agar [8]. MH agar which meets the requirements of the NCCLS standard [8] is considered the reference medium. Supplements should not be used unless necessary for growth of the organisms. Five per cent de¢brinated blood is added for fastidious organisms such as streptococci and Morax- ella catarrhalis. Several supplements for Haemophilus spp. and Neisseria spp. have been suggested but evidence of perfor- mance is needed. Five per cent de¢brinated blood with 20 mg/ L NAD, 5% chocolated blood, and supplemented GC agar have been suggested. ANTIMICROBIAL AGENTS Obtain antimicrobial powders directly from the manufacturer or from commercial sources.The agent must be supplied with a stated potency (mg or International Units per g powder, or as a percentage potency), an expiry date and details of recom- mended storage conditions. Store powders in sealed contain- ers in the dark at 4 C with a desiccant unless otherwise recommended by the manufacturer. Ideally, hygroscopic agents should be dispensed into aliquots, and one aliquot used on each test occasion. Allow containers to warm to room tem- perature before opening them to avoid condensation of water on the powder. Preparation of stock solutions Use an analytical balance when weighing agents. Allowance for the potency of the powder can be made by use of the fol- lowing formula: Weight of powder …mg† ˆ Volume of solvent …mL† Â Concentration …mgaL† Potency of powder …mgag† Alternatively, given a weighed amount of antimicrobial pow- der, the volume of diluent needed may be calculated from the formula: Weight of solvent …mL† ˆ Weight of powder …mg† Â Potency of powder …mgag† Concentration …mgaL† Concentrations of stock solutions should be 1000 mg/L or greater, although the solubility of some agents will be limit- ing. The actual concentrations of stock solutions will depend on the method of preparing working solutions. Manufac- turers' recommendations for solvents and diluents should be followed, but where possible agents should be dissolved and diluted in sterile distilled water. Some agents that require alternative solvents are listed in Table1. Sterilization of solu- tions is not usually necessary. If required, sterilization should EUCAST DEFINITIVE DOCUMENT E.Def 3.1 JUNE 2000 = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
  • 2. be by membrane ¢ltration, and samples before and after steri- lization must be compared by assay to ensure that adsorption to the membrane has not occurred. Unless otherwise instructed by the manufacturer, store stock solutions frozen in aliquots at À20 C or below. Most agents will keep at À60 C for at least 6 months. Stock solutions must be frozen as soon as possible after preparation, used promptly on defrosting and not re-frozen. Preparation of working solutions The range of concentrations tested will depend on the organ- isms and antimicrobial agent being tested, but a two-fold dilution series based on 1mg/L is conventionally used. Twenty-milliliter volumes of agar are commonly used in 9- cm Petri dishes for agar dilution MICs. Two alternative dilu- tion schemes are given inTables 3 and 4. Both schemes involve adding 19-mL volumes of molten agar to 1-mL volumes of antimicrobial solution. The more conventional method is based on diluting a 10 240 mg/L stock solution, always mea- suring 1-mL volumes of antimicrobial solution (Table 2). The other method (Table 3) is based on diluting a 10 000 mg/L stock solution and involves measuring various volumes of antimicrobial solution by the use of high-precision variable- volume micropipettes, which are now widely available. An alternative to the method in Table 3 is to omit the distilled water added to make antimicrobial volumes up to 1mL and instead to add a variable volume of molten agar to make the total volume 20 mL. PREPARATION OF PLATES Prepare agar as recommended by the manufacturer. Allow the sterilized agar to cool to 50 C in a water-bath. Prepare a dilution series of antimicrobial agents, as above, in 25^30-mL containers. Include a drug-free control. Add 19 mL of molten agar to each container, mix thoroughly, and pour the agar into prelabeled sterile Petri dishes on a level surface. Allow the plates to set at room temperature and dry the plates so that no drops of moisture remain on the surface of the agar. Do not overdry plates. Plates should not be stored unless the agents have been shown to be stable on storage. Clavulanic acid and carbape- nems are particularly unstable. Table1 Solvents and diluents for antimicrobial agents requiring solvents other than water Antimicrobial agent Solvent Diluent Amoxycillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0 Ampicillin Phosphate buffer 0.1 M, pH 8.0 Phosphate buffer 0.1 M, pH 6.0 Azithromycin Ethanol 95% Water Aztreonam Saturated sodium bicarbonate solution Water Ceftazidime Saturated sodium bicarbonate solution Water Chloramphenicol Ethanol 95% Water Clavulanic acid Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0 Erythromycin Ethanol 95% Water Fluoroquinolones Half volume water, a minimum volume of 0.1 M NaOH to dissolve, then make up to total volume with water Water Fusidic acid Ethanol 95% Water Imipenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2 Mezlocillin Methanol Water Meropenem Phosphate buffer 0.01 M, pH 7.2 Phosphate buffer 0.01 M, pH 7.2 Nalidixic acid Half volume water, a minimum volume of 0.1 M NaOH to dissolve, then make up to total volume with water Water Nitrofurantoin Dimethylformamide Phosphate buffer 0.1 M, pH 8.0 Rifampicin Methanol Water Sulbactam Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0 Sulfonamides Half volume water, a minimum volume of 0.1 M NaOH to dissolve, then make up to total volume with water Water Ticarcillin Phosphate buffer 0.1 M, pH 6.0 Phosphate buffer 0.1 M, pH 6.0 Trimethoprim Half volume water, a minimum volume of 0.1 M lactic acid or 0.1 M HCl to dissolve, then make up to total volume with water Water äò Clinical Microbiology and Infection, Volume 6 Number 9, September 2000 = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
  • 3. Table 2 Preparation of dilutions of agents for use in agar dilution susceptibility tests Antimicrobial concentration (mg/L) in stock solution Volume stock solution (mL) Volume distilled water (mL) Antimicrobial concentration obtained (mg/L) Final concentration in medium after addition of 19 mL of agar 10 240 1 0 10 240 512 10 240 1 1 5120 256 10 240 1 3 2560 128 2560 1 1 1280 64 2560 1 3 640 32 2560 1 7 320 16 320 1 1 160 8 320 1 3 80 4 320 1 7 40 2 40 1 1 20 1 40 1 3 10 0.5 40 1 7 5 0.25 5 1 1 2.5 0.125 5 1 3 1.25 0.06 5 1 7 0.625 0.03 0.625 1 1 0.3125 0.015 0.625 1 3 0.1562 0.008 0.625 1 7 0.0781 0.004 Table 3 Alternative method of preparation of dilutions of antimicrobial agents for use in agar dilution susceptibility tests Antimicrobial concentration (mg/L) in stock Volume stock solution (mL) Volume distilled water (mL) Antimicrobial concentration obtained (mg/L) Final concentration in medium after addition of 19 mL of agar 10 000 1 9 1000 ± 10 000 0.1 9.9 100 ± 100 1 9 10 ± 100 0.1 9.9 1 ± 10 000 1.024 0 10 240 512 10 000 0.512 0.488 5120 256 10 000 0.256 0.744 2560 128 10 000 0.128 0.872 1280 64 1000 0.64 0.36 640 32 1000 0.32 0.68 320 16 1000 0.16 0.84 160 8 100 0.8 0.2 80 4 100 0.4 0.6 40 2 100 0.2 0.8 20 1 10 1 0 10 0.5 10 0.5 0.5 5 0.25 10 0.25 0.75 2.5 0.125 10 0.125 0.875 1.25 0.06 1 0.625 0.375 0.625 0.03 1 0.313 0.687 0.3125 0.015 1 0.156 0.844 0.1562 0.008 1 0.078 0.922 0.0781 0.004 äEUCAST De®nitive Document = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
  • 4. PREPARATION OF INOCULUM Standardize the density of inoculum to give 104 colony-form- ing units (CFU) per spot on the agar. Use four or ¢ve colonies of a pure culture to avoid selecting an atypical variant. The inoculum may be prepared by emulsifying overnight colonies from an agar medium or by diluting a broth culture.The broth used must not be antagonistic to the agent tested. A 0.5 McFar- land standard may be used for visual comparison to adjust the suspension to a density equivalent to approximately 108 CFU/ mL. Alternatively, inocula can be adjusted photometrically. Dilute the suspensions of organisms in 0.85% saline or broth to give 107 CFU/mL. Plates must be inoculated within 30 min of standardizing the inoculum, to avoid changes in inoculum density. INOCULATION OF PLATES Mark the plates so that the orientation is obvious. Transfer diluted bacterial suspensions to the wells of an inoculum- replicating apparatus. Use the apparatus to transfer the inocula to the series of agar plates, including a control plate without antimicrobial agent. Replicator pins 2.5 mm in diameter will transfer about1 mL, i.e. an inoculum of104 CFU/spot. Alterna- tively, a micropipette or standard loop may be used to inocu- late plates. Allow the inoculum spots to dry at room temperature before inverting the plates for incubation. INCUBATION OF PLATES Incubate plates at 35^37 C in air for 18 h. In order to avoid uneven heating, do not stack plates more than ¢ve high. If the incubation period is extended for slow-growing organisms, the stability of the agent over the incubation period must be assessed by the inclusion of control strains with known MICs. Avoid incubation in an atmosphere containing 5% CO2 unless necessary for growth of the organisms (e.g. Neisseria spp.). Incubate methicillin/oxacillin susceptibility tests on staphylo- cocci at 30 C. READING RESULTS The MIC is the lowest concentration of the agent that comple- tely inhibits visible growth as judged by the naked eye, disre- garding a single colony or a thin haze within the area of the inoculated spot. A trailing endpoint with a small number of colonies growing on concentrations several dilutions above that which inhibits most organisms should be investigated by subculture and retesting. Such trailing endpoints may indicate contamination, resistant variants, b-lactamase-producing organisms, or, if incubation is prolonged, regrowth of suscep- tible organisms following deterioration of the agent. With sulfonamides and trimethoprim, endpoints may be seen as a reduction in growth, and a haze of growth may be seen at sev- eral dilutions above the actual MIC. FASTIDIOUS ORGANISMS Testing of fastidious organisms may require supplementation of the medium, enrichment of the incubation atmosphere with 5% CO2, or extension of the incubation time.The e¡ect of any alterations in test conditions must be assessed by the inclusion of appropriate control organisms. METHICILLIN/OXACILLIN SUSCEPTIBILITY TESTS ON STAPHYLOCOCCI A combination of test conditions a¡ects the expression of intrinsic resistance to b-lactam agents in staphylococci. The following apply to tests with staphylococci and all b-lactam agents: 1. Add 2% NaCl to the medium. 2. Incubate tests at 30 C (note that some coagulase-negative strains do not grow well at 30 C and may require incubation for 48 h). 3. Incubate tests for 24 h. Continue incubation for a further 24 h for coagulase-negative staphylococci. Penicillinase hyperproducing strains of Staphylococcus aureus may have methicillin/oxacillin MICs raised by one or two two-fold dilution steps compared with other penicillinase- producing strains. TESTS ON bb-LACTAMASE-PRODUCING ORGANISMS When testing organisms that produce extracellular b-lacta- mases, the MICs of penicillins and cephalosporins may be markedly a¡ected by the density of inoculum. The standard inoculum may result in MICs only slightly higher than those obtained with susceptible strains. b-Lactamase production can be more reliably detected in staphylococci, gonococci, Haemo- philus in£uenzae and Moraxella catarrhalis by de¢nitive tests such as nitroce¢n-based techniques. Among Gram-negative organisms, the e¡ect of the inoculum depends on the amount of enzyme produced, and the activity of the enzyme against the particular penicillin or cephalosporin under test. E¡ective standardization of the inoculum is necessary to avoid large variations in MIC results. QUALITY CONTROL Routine quality control is achieved by the use of control strains, e.g. as shown in Table 4. Working cultures of control strains may be stored on digest agar slopes and subcultured äá Clinical Microbiology and Infection, Volume 6 Number 9, September 2000 = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
  • 5. Table4TargetMICsforcontrolorganismsonMueller±Hinton(MH)andIso-Sensitest(IS)mediawithoutblood Antimicrobialagent Escherichia coli ATCC25922 NCTC12241 CIP76.24 MH(IS)agar Escherichia coli ATCC10536 NCTC10418 CIP54.127 ISagar Pseudomonas aeruginosa ATCC27853 NCTC12934 CIP76.110 (MH)ISagar Pseudomonas aeruginosa ATCC25668 NCTC10662 CIP103837 ISagar Staphylococcus aureus ATCC29213 NCTC12973 CIP103429 MH(IS)agar Staphylococcus aureus ATCC9144 NCTC6571 CIP53.154 ISagar Enterococcus faecalis ATCC29212 NCTC12697 CIP103214 MH(IS)agar Amikacin1(1)0.52(2)22(2)1128(128) Ampicillin4(4)2±±0.50.061(1) Amoxycillin4(4)2±±±0.125±(0.5) Amoxycillin/clavulanicacid4/2(4/2)2/1±±±(0.25/0.125)0.125/0.060.5/0.25(0.5/0.25) Azithromycin±±±±1(0.125)0.125 Aztreonam0.125(0.25)0.034(2)4±±± Carbenicillin82323240.532 Cefaclor2(2)1±±2(1)1± Cefamandole0.5±±0.50.25± Cefazolin2±±±0.5±± Cefepime0.03±2(2)±2±± Ce®xime0.5(0.25)0.06±1616(16)8± Cefonicid0.5±±±2±± Cefoperazone0.25±4±2±± Cefotaxime0.125(0.06)0.038(8)82(1)0.5±(32) Cefotetan0.1250.06±±84± Cefoxitin24±±22± Cefpirome±(0.03)0.03±(1)4±(0.5)±±(16) Cefpodoxime0.5(0.25)0.25±1282(2)0.25± Cefsulodin±±±2±±± Ceftazidime0.125(0.25)0.062(1)18(8)1± Ceftizoxime0.060.00832±42± Ceftriaxone0.060.0316(8)82(2)±± Cefuroxime42±±1(1)0.5± Cephalexin8(8)4±±4(4)1± Cephalothin8(8)4±±0.25(0.25)0.5±(16) Cephradine±4±±±2± Chloramphenicol42±1284(2)28(4) Cipro¯oxacin0.0080.0150.5(0.25)0.250.25(0.5)0.1250.5(1) Clarithromycin±±±±0.250.12± Clindamycin±±±±0.125(0.06)0.068(8) Colistin10.50.52±±± Enoxacin0.1250.254110.54 Erythromycin±±±±0.5(0.25)0.1252(4) Fleroxacin0.060.06210.50.54 Fusidicacid±±±±±(0.06)0.06±(2) Gati¯oxacin±0.015±1±0.03± äâEUCAST De®nitive Document = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
  • 6. Antimicrobialagent Escherichia coli ATCC25922 NCTC12241 CIP76.24 MH(IS)agar Escherichia coli ATCC10536 NCTC10418 CIP54.127 ISagar Pseudomonas aeruginosa ATCC27853 NCTC12934 CIP76.110 (MH)ISagar Pseudomonas aeruginosa ATCC25668 NCTC10662 CIP103837 ISagar Staphylococcus aureus ATCC29213 NCTC12973 CIP103429 MH(IS)agar Staphylococcus aureus ATCC9144 NCTC6571 CIP53.154 ISagar Enterococcus faecalis ATCC29212 NCTC12697 CIP103214 MH(IS)agar Gentamicin0.5(0.5)0.251(1)20.25(0.25)0.1258(8) Imipenem0.125(0.125)0.062(1)20.03(0.015)0.0151(0.5) Kanamycin2(1)1±12232 Levo¯oxacin0.0160.031(0.5)0.50.125(0.25)0.1250.5 Linezolid±±±±±0.5± Loracarbef1(1)0.5±±1(1)0.5± Mecillinam±(0.125)0.125±8±(64)8± Methicillin±±±±1(2)1± Meropenem0.016(0.008)0.0150.5(0.25)20.06(0.06)0.034(2) Mezlocillin4216820.52 Moxalactam0.250.0316888± Moxi¯oxacin±0.03±(2)2±0.06±(0.25) Mupirocin±±±±±(0.125)0.25± Nalidixicacid22±±±(128)±± Neomycin±±±32±0.125± Netilmicin0.50.521±0.258 Nitrofurantoin84±±16(16)88(8) Nor¯oxacin0.060.062(1)11(1)0.252(2) O¯oxacin0.030.062(1)10.250.252(2) Oxacillin±±±±0.25(0.5)0.25± Pe¯oxacin±0.06±0.5±0.25± Penicillin±±±±0.5(0.125)0.032(2) Piperacillin2(2)0.52(2)42(1)0.252(2) Piperacillin/tazobactam2/4±2/4±0.5/4±2/4 Quinupristin/dalfopristin±±±±0.5(0.25)0.1254(1) Rifampicin161632±0.016(0.004)0.0042(2) Sul®soxazole16±±±64±64 Sulfamethoxazole±16±±±64± Teicoplanin±±±±0.5(0.5)0.250.125(0.25) Temocillin±2±±±±± Tetracycline2116(32)±0.5(0.5)0.12516(16) Ticarcillin41161640.532 Ticarcillin/clavulanicacid4/2±16/2(16/4)32/41/2±32/2 Tobramycin0.5(0.5)0.250.5(0.5)0.50.25(0.5)0.12516 Trimethoprim10.125±322(0.5)0.25±(0.25) Trimethoprim/sulfamethoxazole±±±±±±± Vancomycin±±±±1(1)0.52(2) ATCCistheAmericanTypeCultureCollection,12301ParklawnDrive,Rockville,MD20852,USA.NCTCistheNationalCollectionofTypeCultures,CentralPublicHealthLaboratory,61 ColindaleAvenue,LondonNW95HT,UK.CIPisCollectiondel'InstitutPasteur,25±28RueduDocteurRoux,75724ParisCedex15,France. Table4continued äã Clinical Microbiology and Infection, Volume 6 Number 9, September 2000 = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515
  • 7. weekly. Working cultures should be replaced monthly from lyophilized or frozen cultures (at À60 C or below). Test colonies of control cultures as recommended for test cultures. Include control cultures with each batch of tests, and test new lots of agar before they are used routinely. In general, MICs of control organisms should be within one two-fold dilution step of the target values given in Table 4. As well as target values for tests on the reference medium, MH agar, tar- get values for control strains tested on Iso-Sensitest agar are included for comparison. In addition: 1. The control plate without antimicrobial agents must show adequate growth of both test and control strains. 2. Plate a sample of inoculum prepared for each strain on a suitable agar medium to ensure that the inoculum is apure cul- ture. 3. Occasionally check that the method of producing the cor- rect inoculum density is working by counting the number of organisms in the inocula. 4. Check that endpoints are read consistently by all sta¡ inde- pendently reading a selection of tests. REVISIONS Proposals for revisions of this document should be sent to EUCAST via EUCAST Secretariat, Cornelia Hasselmann, Martin-Buber-Weg 17, D-81245 Munich, Germany (Fax: ‡ 49 89 89712004; E-mail: Cornelia.Hasselmann@t-online.de) REFERENCES 1. Ericsson H, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand Sect B 1971; 217(suppl): 1^90. 2. Comite¨ l'Antibiogramme de la Socie¨ te¨ Franc,aise de Microbiologie. Technical recommendations for in vitro susceptibility testing. Clin Microbiol Infect1996; 2(suppl1): S11^25. 3. Deutsches Institut fu« r Normung. Methods for the determination of sus- ceptibility of pathogens (except mycobacteria) to antimicrobial agents. MIC breakpoints of antibacterial agents. Berlin: DIN, 1998; suppl 1: 58940^ 4. 4. Norwegian Working Group on Antibiotics. Susceptibility testing of bacteria and fungi. ScandJInfectDis1997;103(suppl): 1^36. 5. Olsson-Liljequist B, Larsson P,Walder M, Mio« rner H. Antimicro- bial susceptibility testing in Sweden III. Methodology for suscept- ibility testing. ScandJInfectDis1997;105(suppl): 13^23. 6. BSAC Working Party. A guide to sensitivity testing. J Antimicrob Chemother1991; 27(suppl D):1^50. 7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that growaerobically, 5th edn. Approved Standard M7-A5.Wayne, PA: NCCLS, 2000. 8. National Committee for Clinical Laboratory Standards. Protocols for evaluating dehydrated Mueller^Hinton agar. Approved Standard M6- A.Wayne, PA: NCCLS,1996. ääEUCAST De®nitive Document = 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 509±515